Armata gets $3.7M from U.S. DoW for AP-SA02 Phase 3 program

September 23, 2026 7:01 AM

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has received $3.7 million in non-dilutive funding from the U.S. Department of War to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found